Découvrez nos professeurs et professeures!

Jean-Mathieu Beauregard

Médecin clinicien enseignant agrégé

Jean-Mathieu Beauregard
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer de l'appareil digestif
  • Cancer la prostate
  • Radiothérapie
  • Cancers hormonaux-dépendants

Projets de recherche

  • Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice - Instituts de recherche en santé du Canada - Subvention Projet, chercheur principal - 2022-04-01 au 2027-03-31
  • Fonds institutionnel d'exploitation des infrastructures pour l'Université Laval - Fondation Canadienne pour l'innovation (La) - Fonds d'exploitation des infrastructures (FEI), co-chercheur - 2002-04-01 au 2025-03-31
  • Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants - Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, co-chercheur - 2022-04-01 au 2024-12-31
  • Théranostique personnalisée du cancer de la prostate - Fonds de recherche du Québec - Santé - Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, chercheur principal - 2022-07-01 au 2024-06-30
  • National Program on Radioligand Therapy for Prostate Cancer - Cancer de la prostate Canada, BC Cancer Agency, co-chercheur - 2018-01-01 au 2022-12-31
  • Chemotherapy-induced upregulation of somatostatin receptors for enhancing therapeutic efficacy of, and eligibility to PRRT of neuroendocrine tumors - Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, co-chercheur - 2020-07-01 au 2022-12-31
  • Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée - Fonds de recherche du Québec - Santé - ONCOPOLE EMC2: Équipes multi-institutionnelles contre le cancer, Université de Sherbrooke, co-chercheur - 2018-04-01 au 2022-06-30

Publications

  • Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale, Andreas Hallqvist, Johanna Svensson, Linn Hagmarker, Ida Marin, Tobias Rydén, Jean-Mathieu Beauregard, Peter Bernhardt, Biomedicines, 2021, 10.3390/biomedicines9111570
  • Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells, Rashmi G. Shah, Marine A. Merlin, Samuel Adant, Fayçal Zine-Eddine, Jean-Mathieu Beauregard, Girish Shah, Cancers, 2021, 10.3390/cancers13020232
  • Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction, Frezza, A., Desport, C., Uribe, C., Zhao, W., Celler, A., Després, P., Beauregard, J.-M., EJNMMI Physics, 2020, 10.1186/s40658-020-0275-6
  • GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome, Meziou, S., Ringuette Goulet, C., Hovington, H., Lefebvre, V., Lavallée, É., Bergeron, M., Brisson, H., Champagne, A., Neveu, B., Lacombe, D., Beauregard, J.-M., Buteau, F.-A., Riopel, J., Pouliot, F., Prostate Cancer and Prostatic Diseases, 2020, 10.1038/s41391-020-0202-x
  • Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT, Desy, A., Bouvet, G.F., Frezza, A., Després, P., Beauregard, J.-M., EJNMMI Physics, 2020, 10.1186/s40658-020-00303-0
  • Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours., Adant S, Shah GM, Beauregard JM, European journal of nuclear medicine and molecular imaging, 2019, 10.1007/s00259-019-04499-x
  • Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study., Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A, Physics in medicine and biology, 2019, 10.1088/1361-6560/ab3039
  • Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations., Hou X, Zhao W, Beauregard JM, Celler A, Physics in medicine and biology, 2019, 10.1088/1361-6560/ab32a1
  • Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma., Schneider JR, Shatzkes DR, Scharf SC, Tham TM, Kulason KO, Buteau FA, Del Prete M, Chakraborty S, Anderson TA, Asiry S, Beauregard JM, Langer DJ, Boockvar JA, Operative neurosurgery (Hagerstown, Md.), 2018, 10.1093/ons/opy028
  • Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial., Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM, European journal of nuclear medicine and molecular imaging, 2018, 10.1007/s00259-018-4209-7
  • Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT., Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM, EJNMMI physics, 2018, 10.1186/s40658-018-0224-9
  • Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy., Arsenault F, Beauregard JM, Pouliot F, Current opinion in supportive and palliative care, 2018, 10.1097/spc.0000000000000357
  • Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes., Zhao W, Esquinas PL, Hou X, Uribe CF, Gonzalez M, Beauregard JM, Dewaraja YK, Celler A, EJNMMI physics, 2018, 10.1186/s40658-018-0208-9
  • Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor., Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM, Oncotarget, 2018, 10.18632/oncotarget.25266
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • A CZT-based blood counter for quantitative molecular imaging., Espagnet R, Frezza A, Martin JP, Hamel LA, Lechippey L, Beauregard JM, Després P, EJNMMI physics, 2017, 10.1186/s40658-017-0184-5
  • Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study., Del Prete M, Buteau FA, Beauregard JM, European journal of nuclear medicine and molecular imaging, 2017, 10.1007/s00259-017-3688-2
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study., Uribe CF, Esquinas PL, Tanguay J, Gonzalez M, Gaudin E, Beauregard JM, Celler A, EJNMMI physics, 2017, 10.1186/s40658-016-0170-3
  • How we read FCH-PET/CT for prostate cancer., Beauregard JM, Beaulieu A, Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, 10.1186/s40644-016-0101-5
  • Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers., Bensaïdane MR, Beauregard JM, Poulin S, Buteau FA, Guimond J, Bergeron D, Verret L, Fortin MP, Houde M, Bouchard RW, Soucy JP, Laforce R, Journal of Alzheimer's disease : JAD, 2016, 10.3233/jad-151180
  • Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes., Bergeron D, Beauregard JM, Guimond J, Fortin MP, Houde M, Poulin S, Verret L, Bouchard RW, Laforce R, Journal of Alzheimer's disease : JAD, 2016, 10.3233/jad-150302
  • Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas., Iliuta IA, Beauregard JM, Couture F, Douville P, Mac-Way F, Clinical nuclear medicine, 2015, 10.1097/rlu.0000000000000862
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • New developments in the imaging of metastatic prostate cancer., Beauregard JM, Pouliot F, Current opinion in supportive and palliative care, 2014, 10.1097/spc.0000000000000076
  • An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging., Jackson PA, Beauregard JM, Hofman MS, Kron T, Hogg A, Hicks RJ, Medical physics, 2013, 10.1118/1.4824318
  • Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion., Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard JM, Zannino D, Hicks RJ, European journal of nuclear medicine and molecular imaging, 2013, 10.1007/s00259-013-2504-x
  • Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions., Beauregard JM, Giraudet AL, Aide N, Hofman MS, Blum R, Drummond E, Roselt P, Hicks RJ, Nuclear medicine communications, 2013, 10.1097/mnm.0b013e3283606669
  • Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer., Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, Bardet S, Gervais R, Lemoel G, Zalcman G, Aide N, Clinical nuclear medicine, 2012, 10.1097/rlu.0b013e318251e3d1
  • 68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy., Hofman MS, Beauregard JM, Barber TW, Neels OC, Eu P, Hicks RJ, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, 10.2967/jnumed.111.093344
  • The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy., Beauregard JM, Hofman MS, Kong G, Hicks RJ, European journal of nuclear medicine and molecular imaging, 2011, 10.1007/s00259-011-1937-3
  • A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors., Aide N, Kinross K, Beauregard JM, Neels O, Potdevin T, Roselt P, Dorow D, Cullinane C, Hicks RJ, Molecular imaging and biology, 2011, 10.1007/s11307-010-0378-x
  • Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system., Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ, Cancer imaging : the official publication of the International Cancer Imaging Society, 2011, 10.1102/1470-7330.2011.0012
  • Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer., Beauregard JM, Williams SG, Degrado TR, Roselt P, Hicks RJ, Journal of medical imaging and radiation oncology, 2010, 10.1111/j.1754-9485.2010.02178.x
  • High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications., Aide N, Desmonts C, Beauregard JM, Beyer T, Kinross K, Roselt P, Neels O, Agostini D, Bardet S, Bouvard G, Hicks RJ, European journal of nuclear medicine and molecular imaging, 2010, 10.1007/s00259-009-1352-1
  • Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CT., Beauregard JM, Croteau E, Ahmed N, van Lier JE, Bénard F, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, 10.2967/jnumed.108.057000
  • [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice., Bénard F, Ahmed N, Beauregard JM, Rousseau J, Aliaga A, Dubuc C, Croteau E, van Lier JE, European journal of nuclear medicine and molecular imaging, 2008, 10.1007/s00259-008-0745-x
  • Effective specific activities determined by scintillation proximity counting for production runs of [(18)F]FES and 4F-M[(18)F]FES., Beauregard JM, Croteau E, Ahmed N, Ouellette R, van Lier JE, Bénard F, Nuclear medicine and biology, 2007, 10.1016/j.nucmedbio.2007.01.001
  • Steroid Receptor Imaging in Breast Cancer., Beauregard JM, Turcotte É, Bénard F, PET clinics, 2006, 10.1016/j.cpet.2005.09.006

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Marine Merlin - Doctorat - En cours
  • Alessandro Desy - Doctorat - En cours
  • Atefeh Zamanian - Doctorat - En cours
  • Vincent Forget - Maitrîse avec mémoire - En cours
  • Amélie Arguin-Therrien - Maitrîse avec mémoire - En cours
  • Jean-François Montégiani - Maitrîse avec mémoire - 2014/09
  • Emilie Gaudin - Maitrîse avec mémoire - 2015/05
  • Michela Del Prete - Doctorat - 2019/01
  • Andrea Frezza - Doctorat - 2021/01
  • Samuel Adant - Maitrîse avec mémoire - 2021/09

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine, local 4645
Québec (Québec) G1V 0A6
Canada

Renseignements - Secrétariat
418 656-2690
vdres@fmed.ulaval.ca

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs